Dr. Oxnard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Ave
Moakley 3RD Foor
Boston, MA 02118Phone+1 617-638-6428Fax+1 617-638-5756
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Massachusetts General HospitalResidency, Internal Medicine, 2005 - 2008
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2007 - 2025
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
NY State Medical License 2008 - 2011- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Afatinib With CT and RT for EGFR-Mutant NSCLC Start of enrollment: 2012 Apr 01
- INHERIT EGFR - Studying Germline EGFR Mutations Start of enrollment: 2012 Dec 28
- Sunitinib in Never-Smokers With Lung Adenocarcinoma Start of enrollment: 2013 May 01
- Join now to see all
Publications & Presentations
PubMed
- 604 citationsNoninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNAGeoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Stacy L. Mach, Allison O'Connell
Clinical Cancer Research. 2014-03-15 - 444 citationsProspective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung CancerAdrian G. Sacher, Cloud P. Paweletz, Suzanne E. Dahlberg, Ryan S. Alden, Allison O'Connell
JAMA Oncology. 2016-08-01 - 6 citationsUnique Spectrum of Activating BRAF Alterations in Prostate Cancer.Alex Chehrazi-Raffle, Hanna Tukachinsky, Eamon Toye, Smruthy Sivakumar, Alexa B Schrock
Clinical Cancer Research. 2023-10-02
Journal Articles
- Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small Cell Lung CancerG R Oxnard, G M Blumenthal, P G Kluetz, R Pazdur, Annals of Oncology
- Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer PopulationKhanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation
Lectures
- Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis.2019 ASCO Annual Meeting - 6/1/2019
- SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung c...2019 ASCO Annual Meeting - 6/1/2019
- Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Join now to see all
Authored Content
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Press Mentions
Illumina Posts 78% Revenue Growth as Cancer, DNA Testing Ramp Back UpAugust 6th, 2021- Famed Chef Ming Tsai, Whose Spouse Polly Is A Lung Most Cancers Survivor, Introduces A New Tasty Vegan Dish with A Artful Title; How Diet Impacts Well BeingAugust 1st, 2021
- The Next Cancer BreakthroughsMarch 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
